Summary
- Azalea Vision has secured up to €7.5m in EIC Accelerator blended finance.
- The company is developing a medical grade smart contact lens platform combining adaptive optics, microelectronics, liquid crystal technology, and connectivity.
- The funding shows EU deep tech support being used to move regulated health devices from research into clinical evidence and commercial readiness.
Azalea Vision has secured up to €7.5m in European Innovation Council Accelerator funding to move its medical grade smart contact lens platform into clinical development.
The Ghent based healthtech company will receive a package comprising a €2.5m grant and a planned €5m equity investment from the EIC Fund. Azalea said it was the only Belgian company selected in the round, with the funding intended to advance a lens embedded platform that can sense, adapt, and connect in real time.
The company’s technology brings together adaptive optics, custom microelectronics, liquid crystal systems, and connectivity, with ambitions to address vision conditions and support tear based health monitoring. Founded in 2021 as a spinout from imec and Ghent University, Azalea sits in a category where deep tech ambition has to pass through the slower disciplines of medical device regulation, clinical evidence, usability, reimbursement, and manufacturing quality.
That makes the EIC funding more than another startup finance item. Europe has long produced strong healthtech research from universities, hospitals, and semiconductor institutes, but the path from laboratory system to clinically adopted device is difficult. Products that touch the body, collect health data, or influence care decisions require evidence and governance that typical software startups do not face.
Smart lenses also sit at a difficult intersection of hardware, biology, and data. The device must be comfortable, reliable, safe, and manufacturable, while connected functions introduce questions around privacy, cybersecurity, power design, data interpretation, and integration with clinical workflows. A medical grade lens cannot succeed by being clever alone; it must work inside healthcare systems that are cautious by design.
The business relevance lies in how Europe funds the move from research to adoption. The EIC Accelerator is designed for breakthrough deep tech, combining grant funding with equity where companies need support before private capital can comfortably underwrite the risk. In healthtech, that blend can be important because clinical validation and regulatory work consume capital before revenue becomes predictable.
Azalea’s Belgian base also strengthens the Benelux angle in Europe’s health technology landscape. Belgium has significant medical research, semiconductor, and life sciences assets, and imec linked spinouts have often tried to convert advanced sensing and miniaturisation into commercial products. A smart lens platform draws directly on that regional strength because the device requires high precision components and clinical use cases rather than generic digital health software.
The market opportunity is still uncertain. Smart contact lenses have attracted attention for years, but several high profile attempts have struggled against comfort, power, durability, and use case limitations. Success will depend on whether Azalea can show a clear clinical need, a reliable product pathway, and an adoption model that works for clinicians, patients, payers, and manufacturers.
The EIC award gives the company room to move from technical promise towards clinical proof. In European healthtech, that is often the most important threshold. The companies that cross it become credible medical device businesses; those that do not remain impressive demonstrations looking for a healthcare system willing to absorb the risk.
